Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
424
datasets available to search
ShareScore release 0.9.0
Dataset results
424 results for “continuous glucose monitor”
Continuous Glucose Monitoring (CGM) in Prediabetes
ClinicalTrials.gov study NCT07371546. IPD Sharing: NO. Countries: 1. Publications: 19.
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
ClinicalTrials.gov study NCT04320069. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
ClinicalTrials.gov study NCT04424888. IPD Sharing: NO. Countries: 1. Publications: 1.
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
ClinicalTrials.gov study NCT02258373. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes
ClinicalTrials.gov study NCT06331923. IPD Sharing: YES. Countries: 1. Publications: 1.
Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes
ClinicalTrials.gov study NCT01083433. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring
ClinicalTrials.gov study NCT04765358. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes
ClinicalTrials.gov study NCT01908530. IPD Sharing: NO. Countries: 1. Publications: 5.
Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study
ClinicalTrials.gov study NCT05074667. IPD Sharing: YES. Countries: 1. Publications: 1.
Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
ClinicalTrials.gov study NCT01586065. IPD Sharing: NO. Countries: 1. Publications: 1.
Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
ClinicalTrials.gov study NCT00850135. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).
ClinicalTrials.gov study NCT04094064. IPD Sharing: NO. Countries: 1. Publications: 1.
Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery
ClinicalTrials.gov study NCT03353415. IPD Sharing: NO. Countries: 1. Publications: 2.
Assessment of the Impact of Real-Time Continuous Glucose Monitoring on People Presenting With Severe Hypoglycaemia
ClinicalTrials.gov study NCT03748433. IPD Sharing: NO. Countries: 1. Publications: 1.
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
ClinicalTrials.gov study NCT00760526. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
ClinicalTrials.gov study NCT05442853. IPD Sharing: NO. Countries: 1. Publications: 1.
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
ClinicalTrials.gov study NCT01237301. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Continuous glucose monitoring profiles in healthy non-diabetic participants: a multicenter prospective study
Context: Use of continuous glucose monitoring (CGM) is increasing for insulin-requiring patients with diabetes. While data on glycemic profiles of healthy, non-diabetic individuals exists for older sensors, assessment of glycemic metrics with new generation CGM devices is lacking. Objective: To establish reference sensor glucose ranges in healthy, non-diabetic individuals across different age groups, using a current generation CGM sensor. Design: Multicenter, prospective study. Setting: 12 centers within the T1D Exchange Clinic Network. Patients or Participants: Non-pregnant, healthy, non-diabetic children and adults (age ≥6 years); with non-obese body mass index. Intervention: A blinded Dexcom G6 CGM, with once daily calibration, was worn for up to 10 days in each participant. Main Outcome Measure: CGM metrics of mean glucose, hyperglycemia, hypoglycemia, and glycemic variability. Results: 153 participants (age 7-80 years) were included in the analyses. Mean average glucose was 98-99 mg/dL (5.4-5.5 mmol/L) for all age groups except those over 60 years in whom mean average glucose was 104 mg/dL (5.8 mmol/L). The median % time between 70-140 mg/dL (3.9-7.8 mmol/L) was 96% (IQR 93%-98%). Mean within-individual coefficient of variation (CV) was 17±3%. Median time spent with glucose levels >140mg/dL was 2.1% (30 min/day) and <70 mg/dL (3.9 mmol/L) was 1.1% (15 min/day). Conclusion: By assessing across age groups in a healthy, non-diabetic population, normative sensor glucose data have been derived, and will be useful as a benchmark for future research studies.
Continuous glucose monitoring in cystic fibrosis: glycemic relationships, clinical correlations, and implications for CFRD diagnosis
<p>Context: The clinical utility and implications of continuous glucose monitoring (CGM) in cystic fibrosis (CF) are unclear.</p> <p>Objective: We examined the correlation between CGM measures and clinical outcomes in adults with CF, investigated the relationship between hemoglobin A1c (HbA1c) and CGM-derived average glucose (AG), and explored CGM measures that distinguish cystic fibrosis–related diabetes (CFRD) from normal and abnormal glucose tolerance.</p> <p>Methods: This prospective observational study included 77 adults with CF who had CGM and HbA1c measured at 2 to 3 time points 3 months apart.</p> <p>Results: Thirty-one of the 77 participants met American Diabetes Association–recommended diagnostic criteria for CFRD by oral glucose tolerance testing and/or HbA1c. In all participants, CGM measures of hyperglycemia and glycemic variability correlated with nutritional status and pulmonary function. HbA1c was correlated with AG (R2 = 0.71, P < 0.001), with no significant difference between this regression line and that previously established in type 1 and type 2 diabetes and healthy volunteers. Cutoffs of 17.5% time > 140 mg/dL and 3.4% time > 180 mg/dL had sensitivities of 87% and 90%, respectively, and specificities of 95%, for identifying CFRD. Area under the curve and percent of participants correctly classified with CFRD were higher for AG, SD, % time > 140, > 180, and > 250 mg/dL than for HbA1c.</p> <p>Conclusion: CGM measures of hyperglycemia and glycemic variability are superior to HbA1c in distinguishing those with and without CFRD. CGM-derived AG is strongly correlated with HbA1c in adults with CF, with a similar relationship to other diabetes populations. Future studies are needed to investigate CGM as a diagnostic and screening tool for CFRD.</p>
Dexcom G6 Continuous Glucose Monitoring in Hemodialysis
ClinicalTrials.gov study NCT04217161. IPD Sharing: Not stated. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.